Investigation of the efficacy and safety of high-dose clarithromycin in adult patients with community-acquired pneumonia-multicenter,single-group,open-label study
Not Applicable
- Conditions
- Adult community-acquired pneumonia
- Registration Number
- JPRN-UMIN000016277
- Lead Sponsor
- Department of medicine, Division of clinical infectious diseases, School of medicine, Showa university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have previously experienced anaphylaxis reactions to the investigational drug or other drugs (2) Patients who are treated with pimozide- or ergotamine-containing drugs or tadalafil (3) Patients determined to be ineligible for the study due to liver disease, kidney disease, heart disease or other serious complications (4) Pregnant or lactating females and females who are suspected of being pregnant (5) Patients assessed by the principal investigator or sub-investigator as
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Based on clinical findings from observations and laboratory tests, the clinical efficacy of the investigational drug will be determined at the completion or discontinuation of treatment, in accordance with the guidelines for assessment of effectiveness of pneumonia treatment established by the Japanese Society of Chemotherapy. All adverse events during the treatment period (from the start of treatment with investigational drug until the completion or discontinuation of treatment with investigational drug) will be investigated.
- Secondary Outcome Measures
Name Time Method